We are live on ! Find out more
ADIL

Adial Pharmaceuticals
ADIL

15 hedge funds and large institutions have $70.2K invested in Adial Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

25% more funds holding

Funds holding: 12 → 15 (+3)

0.05% less ownership

Funds ownership: 0.14% → 0.09% (-0.05%)

54% less capital invested

Capital invested by funds: $151K → $70.2K (-$81.2K)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$15K
2
HF
HRT Financial
New York
+$11.5K
3
Two Sigma Investments
Two Sigma Investments
New York
+$6.52K
4
Citigroup
Citigroup
New York
+$2.4K
5
SHIM
Stone House Investment Management
Pennsylvania
+$1.63K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$21.4K
2
VF
Virtu Financial
New York
-$17K
3
1IA
1620 Investment Advisors
Massachusetts
-$2.28K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$20.8K – – –
MCM
2
Manchester Capital Management
Vermont
$14.5K – – –
BlackRock
3
BlackRock
New York
$8.39K – – –
Jane Street
4
Jane Street
New York
$7.51K +$15K +994 New
HF
5
HRT Financial
New York
$5K +$11.5K +764 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.97K – – –
UBS Group
7
UBS Group
Switzerland
$3.74K -$21.4K -1,414 -74%
Two Sigma Investments
8
Two Sigma Investments
New York
$3.26K +$6.52K +432 New
Citigroup
9
Citigroup
New York
$1.2K +$2.4K +159 New
SHIM
10
Stone House Investment Management
Pennsylvania
$816 +$1.63K +108 New
TRCT
11
Tower Research Capital (TRC)
New York
$429 – – –
SS
12
SBI Securities
Japan
$398 +$242 +16 +43%
Wells Fargo
13
Wells Fargo
California
$48 – – –
Bank of America
14
Bank of America
North Carolina
$22 +$15 +1 +50%
AWM
15
Abound Wealth Management
Tennessee
$9 – – –
Morgan Stanley
16
Morgan Stanley
New York
$3 – – –
VF
17
Virtu Financial
New York
– -$17K -1,057 Closed
1IA
18
1620 Investment Advisors
Massachusetts
– -$2.28K -144 Closed

ADIL Hedge Fund Activity: Q2 2025 in Review

15 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2025, worth a combined $70.2K — down 54% from $151K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ADIL positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $15K. The largest seller was UBS Group, cutting an estimated $21.4K.

  • 15 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2025, up from 12 in Q1 2025.
  • Funds reported $70.2K of Adial Pharmaceuticals stock for Q2 2025, down 54% quarter-over-quarter.
  • 5 funds opened new Adial Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +3 holders.
  • The largest Adial Pharmaceuticals buyer in Q2 2025 was Jane Street, an estimated $15K added.
  • The largest Adial Pharmaceuticals seller in Q2 2025 was UBS Group, an estimated $21.4K sold.

Based on aggregated 13F filings for Q2 2025.